Interestingly another Trop-2 targeting ADC, datopotamab deruxtecan (Dato-DXd, DS-1062a), which is also conjugated to a potent DNA topoisomerase I inhibitor is under investigation in a phase I/II clinical trial NCT04644068 in combination with the oral PARP inhibitor AZD5305 for a range of solid cancers including pancreatic cancer. This evidence concerns the gene TACSTD2 and pancreatic neoplasm.